Literature DB >> 15016842

Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.

Evguenia S Svarovskaia1, Rebekah Barr, Xuechun Zhang, Godwin C G Pais, Christophe Marchand, Yves Pommier, Terrence R Burke, Vinay K Pathak.   

Abstract

We previously found that azido-containing beta-diketo acid derivatives (DKAs) are potent inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase (IN) (X. Zhang et al., Bioorg. Med. Chem. Lett., 13:1215-1219, 2003). To characterize the intracellular mechanisms of action of DKAs, we analyzed the antiviral activities of two potent azido-containing DKAs with either a monosubstitution or a disubstitution of azido groups, using single- and multiple-replication-cycle assays. Both azido-containing DKAs significantly inhibited HIV-1 infection in 293T, CEM-SS, and H9 cells (50% inhibitory concentration = 2 to 13 micro M) and exhibited low cytotoxicity (50% cytotoxic concentration = 60 to 600 micro M). Inhibition of HIV-1 IN in vivo was demonstrated by the observation that previously described L-708,906 resistance mutations in HIV-1 IN (T66I and T66I/S153Y) also conferred resistance to the azido-group-containing DKAs. In vitro assays and in vivo analysis indicated that the DKAs did not significantly inhibit the 3' processing and selectively inhibited the strand transfer reaction. In addition, quantitative PCR indicated that two-long-terminal-repeat (2-LTR) circles were elevated in the presence of the azido-containing DKAs, confirming that HIV-1 IN was the intracellular target of viral inhibition. To gain insight into the mechanism by which the DKAs increased 2-LTR-circle formation of 3'-processed viral DNAs, we performed extensive DNA sequencing analysis of 2-LTR-circle junctions. The results indicated that the frequency of deletions at the circle junctions was elevated from 19% for the untreated controls to 32 to 41% in the presence of monosubstituted (but not disubstituted) DKAs. These results indicate that the structure of the DKAs can influence the extent of degradation of viral DNA ends by host nucleases and the frequency of deletions at the 2-LTR-circle junctions. Thus, sequencing analysis of 2-LTR-circle junctions can elucidate the intracellular mechanisms of action of HIV-1 IN inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016842      PMCID: PMC371038          DOI: 10.1128/jvi.78.7.3210-3222.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

Review 1.  S-1360 Shionogi-GlaxoSmithKline.

Authors:  Andreas Billich
Journal:  Curr Opin Investig Drugs       Date:  2003-02

Review 2.  HIV entry inhibitors in clinical development.

Authors:  Bryan M O'Hara; William C Olson
Journal:  Curr Opin Pharmacol       Date:  2002-10       Impact factor: 5.547

3.  Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid.

Authors:  Cathryn A Shaw-Reid; Vandna Munshi; Pia Graham; Abigail Wolfe; Marc Witmer; Renee Danzeisen; David B Olsen; Steven S Carroll; Mark Embrey; John S Wai; Michael D Miller; James L Cole; Daria J Hazuda
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

4.  Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication.

Authors:  Saori Matsuoka-Aizawa; Hironori Sato; Atsuko Hachiya; Kiyoto Tsuchiya; Yutaka Takebe; Hiroyuki Gatanaga; Satoshi Kimura; Shinichi Oka
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.

Authors:  Peter J King; Deborah J Lee; Ryan A Reinke; Joseph G Victoria; Keola Beale; W Edward Robinson
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

6.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases.

Authors:  F Dyda; A B Hickman; T M Jenkins; A Engelman; R Craigie; D R Davies
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

7.  Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations.

Authors:  Ryan A Reinke; Peter J King; Joseph G Victoria; Brenda R McDougall; Guoxiang Ma; Yingqun Mao; Manfred G Reinecke; W Edward Robinson
Journal:  J Med Chem       Date:  2002-08-15       Impact factor: 7.446

8.  Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors.

Authors:  Xuechun Zhang; Godwin C G Pais; Evguenia S Svarovskaia; Christophe Marchand; Allison A Johnson; Rajeshri G Karki; Marc C Nicklaus; Vinay K Pathak; Yves Pommier; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2003-03-24       Impact factor: 2.823

9.  Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.

Authors:  Linghang Zhuang; John S Wai; Mark W Embrey; Thorsten E Fisher; Melissa S Egbertson; Linda S Payne; James P Guare; Joseph P Vacca; Daria J Hazuda; Peter J Felock; Abigail L Wolfe; Kara A Stillmock; Marc V Witmer; Gregory Moyer; William A Schleif; Lori J Gabryelski; Yvonne M Leonard; Joseph J Lynch; Stuart R Michelson; Steven D Young
Journal:  J Med Chem       Date:  2003-02-13       Impact factor: 7.446

10.  A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes.

Authors:  J K Yee; A Miyanohara; P LaPorte; K Bouic; J C Burns; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

View more
  60 in total

1.  Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients.

Authors:  Roberta Bona; Silvia Baroncelli; Gabriella D'Ettorre; Mauro Andreotti; Giancarlo Ceccarelli; Piero Filati; Pasqualina Leone; Maria Blasi; Zuleika Michelini; Clementina Maria Galluzzo; Alessandra Mallano; Vincenzo Vullo; Andrea Cara
Journal:  AIDS Res Hum Retroviruses       Date:  2013-07-24       Impact factor: 2.205

2.  Correlation of recombinant integrase activity and functional preintegration complex formation during acute infection by replication-defective integrase mutant human immunodeficiency virus.

Authors:  Xiang Li; Yasuhiro Koh; Alan Engelman
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 3.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

4.  EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors.

Authors:  Stephan Kremb; Markus Helfer; Werner Heller; Dieter Hoffmann; Horst Wolff; Andrea Kleinschmidt; Sabine Cepok; Bernhard Hemmer; Jörg Durner; Ruth Brack-Werner
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

5.  New class of HIV-1 integrase (IN) inhibitors with a dual mode of action.

Authors:  Manuel Tsiang; Gregg S Jones; Anita Niedziela-Majka; Elaine Kan; Eric B Lansdon; Wayne Huang; Magdeleine Hung; Dharmaraj Samuel; Nikolai Novikov; Yili Xu; Michael Mitchell; Hongyan Guo; Kerim Babaoglu; Xiaohong Liu; Romas Geleziunas; Roman Sakowicz
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

6.  Differentially stimulated CD4+ T cells display altered human immunodeficiency virus infection kinetics: implications for the efficacy of antiviral agents.

Authors:  Dimitrios N Vatakis; Christopher C Nixon; Gregory Bristol; Jerome A Zack
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

7.  An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Authors:  Benjamin Trinité; Eric C Ohlson; Igor Voznesensky; Shashank P Rana; Chi N Chan; Saurabh Mahajan; Jason Alster; Sean A Burke; Dominik Wodarz; David N Levy
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

8.  Measurement of human immunodeficiency virus type 1 preintegration transcription by using Rev-dependent Rev-CEM cells reveals a sizable transcribing DNA population comparable to that from proviral templates.

Authors:  Subashini R Iyer; Dongyang Yu; Angélique Biancotto; Leonid B Margolis; Yuntao Wu
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

9.  Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein.

Authors:  Christopher J McKee; Jacques J Kessl; Nikolozi Shkriabai; Mohd Jamal Dar; Alan Engelman; Mamuka Kvaratskhelia
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

10.  Tat controls transcriptional persistence of unintegrated HIV genome in primary human macrophages.

Authors:  Beatrix Meltzer; Deemah Dabbagh; Jia Guo; Fatah Kashanchi; Mudit Tyagi; Yuntao Wu
Journal:  Virology       Date:  2018-03-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.